Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.

Published

Journal Article

Sotatercept may represent a novel approach to the treatment of chemotherapy-induced anemia (CIA). We report the results from two phase 2 randomized studies examining the use of sotatercept for the treatment of CIA in patients with metastatic cancer.In study A011-08, patients with metastatic breast cancer were randomized to 2:2:2:1 to receive sotatercept 0.1, 0.3, or 0.5 mg/kg, or placebo, respectively, every 28 days. In study ACE-011-NSCL-001, patients with solid tumors treated with platinum-based chemotherapy received sotatercept 15 or 30 mg every 42 days. The primary endpoint for both studies was hematopoietic response, defined as a hemoglobin (Hb) increase of ≥1 g/dL from baseline.Both studies were terminated early due to slow patient accrual. Among patients treated with sotatercept in the A011-08 and ACE-011-NSCL-001 studies, more patients achieved a mean Hb increase of ≥1 g/dL in the combined sotatercept 0.3 mg/kg and 15 mg (66.7 %) group and sotatercept 0.5 mg/kg and 30 mg (38.9 %) group versus the sotatercept 0.1 mg/kg (0 %) group. No patients achieved a mean Hb increase of ≥1 g/dL in the placebo group. The incidence of treatment-related adverse events (AEs) was low in both studies, and treatment discontinuations due to AEs were uncommon.Although both studies were terminated early, these results indicate that sotatercept is active and has an acceptable safety profile in the treatment of CIA.

Full Text

Duke Authors

Cited Authors

  • Raftopoulos, H; Laadem, A; Hesketh, PJ; Goldschmidt, J; Gabrail, N; Osborne, C; Ali, M; Sherman, ML; Wang, D; Glaspy, JA; Puccio-Pick, M; Zou, J; Crawford, J

Published Date

  • April 2016

Published In

Volume / Issue

  • 24 / 4

Start / End Page

  • 1517 - 1525

PubMed ID

  • 26370220

Pubmed Central ID

  • 26370220

Electronic International Standard Serial Number (EISSN)

  • 1433-7339

International Standard Serial Number (ISSN)

  • 0941-4355

Digital Object Identifier (DOI)

  • 10.1007/s00520-015-2929-9

Language

  • eng